** Shares of medical device maker Dexcom DXCM.O rise 8.6% to $72.60 premarket
** Co says U.S. FDA has cleared its 15-day continuous glucose monitoring (CGM) device called Dexcom G7 15 Day for people over the age of 18 with diabetes in the United States
** Co says the CGM lasts for 15.5 days and helps in "easier glucose management with fewer monthly sensors and reduced monthly waste"
** Co's other G7 CGM lasts for up to 10 days, while its over-the-counter CGM Stelo also lasts for 15 days
** Approval for co's 15-day CGM should provide momentum through 2025, brokerage William Blair had said in a note in February
** Up to last close, stock had fallen 14.1% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。